Esperion Therapeutics, Inc.
ESPR
$1.50
$0.000.00%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 33.86% | -30.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 33.86% | -30.07% | |||
| Cost of Revenue | 32.24% | 2.26% | |||
| Gross Profit | 35.73% | -48.79% | |||
| SG&A Expenses | -7.63% | -9.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.68% | -5.05% | |||
| Operating Income | 72.42% | -721.40% | |||
| Income Before Tax | 27.79% | 52.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 27.79% | 52.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.79% | 52.32% | |||
| EBIT | 72.42% | -721.40% | |||
| EBITDA | 72.54% | -719.20% | |||
| EPS Basic | 28.05% | 53.81% | |||
| Normalized Basic EPS | 33.69% | -228.82% | |||
| EPS Diluted | 28.05% | 53.81% | |||
| Normalized Diluted EPS | 33.69% | -228.82% | |||
| Average Basic Shares Outstanding | 0.33% | 3.25% | |||
| Average Diluted Shares Outstanding | 0.33% | 3.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
